After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal

Nine years ago, when Michael Morrissey took over the helm at Exelixis as George Scangos headed to Biogen, he made a careful point of circling the wagons around Cabometyx and taking it into the market. Now, he and the executive team are taking another step outside that path as the biotech slowly expands its focus and pipeline.